NCT06233942 2026-03-18
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
9 trialsNCT07300943 2026-03-13
Study in Advanced Solid Tumor Patients
Callio Therapeutics
Phase 1/2 Recruiting
NCT06598800 2026-03-12
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05981703 2026-03-04
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06589596 2026-03-04
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT04855656 2026-02-27
MYTHIC
Debiopharm International SA
Phase 1 Recruiting
NCT06833008 2026-02-27
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT06911827 2026-02-25
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06625593 2026-02-20
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting